ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 759 USD | -2.28% |
|
+4.60% | +30.08% |
| 02:24pm | Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1 | RE |
| 07:42am | Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast | RE |
Financials (USD)
| Sales 2024 * | 43.03B | Sales 2025 * | 51.95B | Capitalization | 699B |
|---|---|---|---|---|---|
| Net income 2024 * | 12.03B | Net income 2025 * | 16.09B | EV / Sales 2024 * | 16.7 x |
| Net Debt 2024 * | 20.93B | Net Debt 2025 * | 13.85B | EV / Sales 2025 * | 13.7 x |
| P/E ratio 2024 * |
57.4
x | P/E ratio 2025 * |
42.8
x | Employees | 43,000 |
| Yield 2024 * |
0.67% | Yield 2025 * |
0.77% | Free-Float | 99.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -1.88% | ||
| 1 week | +5.66% | ||
| Current month | -1.94% | ||
| 1 month | +0.26% | ||
| 3 months | +14.72% | ||
| 6 months | +31.99% | ||
| Current year | +31.39% |
1 week
721.00
795.50
1 month
718.30795.50
Current year
579.05800.78
1 year
414.31800.78
3 years
182.92800.78
5 years
101.36800.78
10 years
57.81800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +3.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 758.1 | -2.40% | 1 515 089 |
| 24-05-01 | 776.8 | -0.56% | 2,804,838 |
| 24-04-30 | 781.1 | +5.95% | 7,437,105 |
| 24-04-29 | 737.2 | +0.50% | 2,732,584 |
| 24-04-26 | 733.5 | +1.19% | 2,009,249 |
Delayed Quote Nyse, May 02, 2024 at 11:20 am EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
776.8
USD
Average target price
845.3
USD
Spread / Average Target
+8.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.39% | 699B | |
| +25.07% | 571B | |
| -4.24% | 364B | |
| +18.30% | 326B | |
| +3.23% | 286B | |
| +14.40% | 236B | |
| +4.61% | 198B | |
| -12.52% | 194B | |
| -4.45% | 154B | |
| -3.82% | 149B |
- Stock Market
- Equities
- LLY Stock
